Shares of Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) reached a new 52-week low during trading on Monday . The stock traded as low as C$1.85 and last traded at C$1.84, with a volume of 13836 shares changing hands. The stock had previously closed at C$1.90.
Aptose Biosciences Trading Down 5.3 %
The company has a debt-to-equity ratio of 14.27, a quick ratio of 5.41 and a current ratio of 0.78. The stock has a market capitalization of C$28.28 million, a P/E ratio of -0.18 and a beta of 1.44. The firm’s fifty day simple moving average is C$2.28 and its 200 day simple moving average is C$2.98.
Aptose Biosciences (TSE:APS – Get Free Report) (NASDAQ:APTO) last released its earnings results on Tuesday, March 26th. The biotechnology company reported C($1.96) EPS for the quarter, beating the consensus estimate of C($1.98) by C$0.02. As a group, equities research analysts forecast that Aptose Biosciences Inc. will post -0.59 EPS for the current fiscal year.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- What is a Low P/E Ratio and What Does it Tell Investors?
- The Charles Schwab Company Can Hit New Highs
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
